Scientific Research on Myopia Management

Myopia typically results from axial lengthening in the eye. To address this, researchers have focused on several promising areas:

• Spectacle Correction

  Glasses have long been studied to inhibit myopia progression. However, while some designs have shown promise, not all have been clinically effective. Recent advancements like the Defocus Incorporated Multiple Segments (DIMS) spectacle lens, designed to induce myopic defocus, have yielded encouraging results. Reducing axial length by 0.30 mm over two years offers a potential solution for myopia control, particularly for children.

• Outdoor Sunlight

  Increasing outdoor time during school has shown a modest but tangible effect on reducing myopia progression. Studies suggest that 40 extra minutes of outdoor exposure daily can make a significant difference. However, the implementation has been challenging, and more research is needed to evaluate the long-term impact across diverse populations.

• Low-dose Atropine

  Low-dose atropine treatment has gained popularity, particularly after studies like the Atropine for the Treatment of Myopia (ATOM) series. While the 0.01% concentration has shown effectiveness, the Low-Concentration Atropine for Myopia Progression (LAMP) study suggests that higher concentrations may offer more profound results. Atropine is easy to implement, especially for young children, with minimal side effects. However, long-term data regarding potential ocular toxicity is still pending.